Technical Analysis for HILS - Hillstream BioPharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 200 DMA Support | Bullish | 2.25% | |
| Outside Day | Range Expansion | 2.25% | |
| Wide Bands | Range Expansion | 2.25% | |
| Oversold Stochastic | Weakness | 2.25% | |
| Narrow Range Bar | Range Contraction | -0.57% | |
| Inside Day | Range Contraction | -0.57% | |
| Wide Bands | Range Expansion | -0.57% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 10 hours ago |
| Down 3% | about 10 hours ago |
| Down 2 % | about 10 hours ago |
| Possible Inside Day | about 10 hours ago |
| Down 1% | about 13 hours ago |
Get a Trading Assistant
- Earnings date: Unknown
Hillstream BioPharma, Inc. Description
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Biology Solid Tumors Tumor Necrosis Anthracycline Treatment Resistant Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.7799 |
| 52 Week Low | 0.303 |
| Average Volume | 3,875,770 |
| 200-Day Moving Average | 0.85 |
| 50-Day Moving Average | 1.04 |
| 20-Day Moving Average | 1.06 |
| 10-Day Moving Average | 0.94 |
| Average True Range | 0.14 |
| RSI | 41.18 |
| ADX | 24.0 |
| +DI | 26.31 |
| -DI | 24.39 |
| Chandelier Exit (Long, 3 ATRs) | 1.03 |
| Chandelier Exit (Short, 3 ATRs) | 1.22 |
| Upper Bollinger Bands | 1.32 |
| Lower Bollinger Band | 0.79 |
| Percent B (%b) | 0.2 |
| BandWidth | 50.44 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0344 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.02 | ||||
| Resistance 3 (R3) | 1.01 | 0.97 | 1.00 | ||
| Resistance 2 (R2) | 0.97 | 0.94 | 0.97 | 0.99 | |
| Resistance 1 (R1) | 0.94 | 0.92 | 0.92 | 0.94 | 0.98 |
| Pivot Point | 0.89 | 0.89 | 0.88 | 0.90 | 0.89 |
| Support 1 (S1) | 0.86 | 0.86 | 0.84 | 0.86 | 0.82 |
| Support 2 (S2) | 0.82 | 0.85 | 0.82 | 0.81 | |
| Support 3 (S3) | 0.78 | 0.82 | 0.80 | ||
| Support 4 (S4) | 0.78 |
